1999
Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental Disorders
Potenza M, Holmes J, Kanes S, McDougle C. Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental Disorders. Journal Of Clinical Psychopharmacology 1999, 19: 37-44.. PMID: 9934941, DOI: 10.1097/00004714-199902000-00008.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderClinical Global Impression ScaleWeight gainTolerability of olanzapineLiver function abnormalitiesExtrapyramidal side effectsGlobal Impression ScaleGlobal improvement itemTreatment of childrenSignificant adverse effectsDevelopmental disordersSelf-injurious behaviorClinical respondersOlanzapine treatmentFunction abnormalitiesDaily doseOverall symptomsPatient populationImpression ScalePrincipal diagnosisMotor restlessnessProspective fashionWeek 4Related symptomsSide effects
1998
Potential of Atypical Antipsychotics in the Treatment of Nonpsychotic Disorders
Potenza M, McDougle C. Potential of Atypical Antipsychotics in the Treatment of Nonpsychotic Disorders. CNS Drugs 1998, 9: 213-232. DOI: 10.2165/00023210-199809030-00005.Peer-Reviewed Original ResearchAtypical antipsychoticsNonpsychotic disordersPharmacological profileDouble-blinded investigationAdverse effect profileUnique pharmacological profileDistinct patient populationsNewer antipsychotic agentsDifferent pharmacological profilesEffect profilePatient populationAntipsychotic agentsAntipsychoticsClinical utilityPsychotic disordersUseful agentPervasive developmental disorderSuch disordersDisordersTolerabilityDrugsFurther studiesTreatmentAggressive behaviorDevelopmental disorders